Homeostasis in the Gut Microbiota in Chronic Kidney Disease

S. Bhargava, E. Merckelbach, H. Noels, A. Vohra, J. Jankowski*

*Corresponding author for this work

Research output: Contribution to journal(Systematic) Review article peer-review

Abstract

The gut microbiota consists of trillions of microorganisms, fulfilling important roles in metabolism, nutritional intake, physiology and maturation of the immune system, but also aiding and abetting the progression of chronic kidney disease (CKD). The human gut microbiome consists of bacterial species from five major bacterial phyla, namely Firmicutes, Bacteroidetes, Actinobacteria, Proteobacteria, and Verrucomicrobia. Alterations in the members of these phyla alter the total gut microbiota, with a decline in the number of symbiotic flora and an increase in the pathogenic bacteria, causing or aggravating CKD. In addition, CKD-associated alteration of this intestinal microbiome results in metabolic changes and the accumulation of amines, indoles and phenols, among other uremic metabolites, which have a feedforward adverse effect on CKD patients, inhibiting renal functions and increasing comorbidities such as atherosclerosis and cardiovascular diseases (CVD). A classification of uremic toxins according to the degree of known toxicity based on the experimental evidence of their toxicity (number of systems affected) and overall experimental and clinical evidence was selected to identify the representative uremic toxins from small water-soluble compounds, protein-bound compounds and middle molecules and their relation to the gut microbiota was summarized. Gut-derived uremic metabolites accumulating in CKD patients further exhibit cell-damaging properties, damage the intestinal epithelial cell wall, increase gut permeability and lead to the translocation of bacteria and endotoxins from the gut into the circulatory system. Elevated levels of endotoxins lead to endotoxemia and inflammation, further accelerating CKD progression. In recent years, the role of the gut microbiome in CKD pathophysiology has emerged as an important aspect of corrective treatment; however, the mechanisms by which the gut microbiota contributes to CKD progression are still not completely understood. Therefore, this review summarizes the current state of research regarding CKD and the gut microbiota, alterations in the microbiome, uremic toxin production, and gut epithelial barrier degradation.
Original languageEnglish
Article number648
Number of pages22
JournalToxins
Volume14
Issue number10
DOIs
Publication statusPublished - 1 Oct 2022

Keywords

  • gut-derived uremic metabolites
  • alterations of the gut microbiome
  • gut permeability
  • pathogenic bacteria in CKD
  • CHAIN FATTY-ACIDS
  • ARYL-HYDROCARBON RECEPTOR
  • TRIMETHYLAMINE-N-OXIDE
  • BOUND UREMIC TOXINS
  • P-CRESYL SULFATE
  • INDOXYL SULFATE
  • BARRIER FUNCTION
  • BACTERIAL TRANSLOCATION
  • INTESTINAL MICROBIOTA
  • PARATHYROID-HORMONE

Cite this